Frontlight ResearchEarly access
CompletedPhase 2
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
Key facts
- Who runs it
- Jiangsu HengRui Medicine Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 120 people enrolled
- Started
- 10 Apr 2025
- Ended
- 9 Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- HRS-8427
- Meropenem
- Record updated
- 22 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Be able and willing to provide a written informed consent before the study, fully understand the study and be able to complete the study according to the protocol
- Male and female, ≥18 years
- Judged by the investigator, clinical diagnosis with HABP/VABP, expectation that the patients will require hospitalization and initial treatment with intravenous antibiotics
- All subjects must have a chest radiograph during screening or within 48h before randomization, showing the presence of new or progressive infiltrate(s) suggestive of bacterial pneumonia
- Women of childbearing potential must have a negative serum pregnancy test before the first dose and must be non-lactating. Fertile female subjects or male subjects whose partner is a fertile female agree to use highly effective form of contraception, with no plan of birth and sperm/ovum donation from the time of signing the informed consent form (ICF) till 14 days after the end of treatment
Who cannot take part
- Subjects who have received potentially effective antibiotic therapy for a continuous duration of more than 24 hours during the previous 72 hours prior to randomization
- Impairment of renal function with estimated glomerular filtration rate < 15 mL/min, or receiving peritoneal dialysis/hemodialysis
- Patients received cancer treatment within 4 weeks before randomization or planned treatment during the study period
- Drug abuse within 1 year prior to randomization
- Other pulmonary diseases that may confound the assessment of efficacy or safety
- Known history of immune deficiency disease or receive immunocompromising treatment
- Severe cardiovascular and cerebrovascular diseases with clinical significance and unstable or uncontrolled condition
- Known or suspected central nervous system infections
- Subjects with significant laboratory abnormalities
- Subjects who have known or suspected community-acquired bacterial pneumonia (CABP), atypical pneumonia, or chemical pneumonia
- Subjects who have known or suspected pneumonia caused by mycoplasma, chlamydia, legionella, viruses, fungi or parasites
- HABP or VABP caused by obstruction
- Judged by the Investigator, other reasons unsuitable for this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy and safety of HRS -8427 in patients with HABP/VABP.
The 2 groups in the trial
- HRS-8427Treatment being tested
- MeropenemExisting treatment, for comparison
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of HRS-8427 in the Treatment of Adults With Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP)
- Publications
- Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections.Antimicrobial agents and chemotherapy, 2026
- Record updated
- 22 October 2026